MA34245B1 - Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc. - Google Patents

Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.

Info

Publication number
MA34245B1
MA34245B1 MA35387A MA35387A MA34245B1 MA 34245 B1 MA34245 B1 MA 34245B1 MA 35387 A MA35387 A MA 35387A MA 35387 A MA35387 A MA 35387A MA 34245 B1 MA34245 B1 MA 34245B1
Authority
MA
Morocco
Prior art keywords
acc
inhibitors
derivatives
bicyclic compounds
compound
Prior art date
Application number
MA35387A
Other languages
English (en)
Inventor
Tohru Yamashita
Makoto Kamata
Hideki Hirose
Masataka Murakami
Takuya Fujimoto
Zenichi Ikeda
Tsuneo Yasuma
Ikuo Fujimori
Ryo Mizojiri
Tomoya Yukawa
Original Assignee
Takeda Pharmaceutcal Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutcal Company Ltd filed Critical Takeda Pharmaceutcal Company Ltd
Publication of MA34245B1 publication Critical patent/MA34245B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne un composé possédant une activité inhibitrice de l'ACC. Ledit composé est utile en tant qu'agent destiné à la prophylaxie et au traitement de l'obésité, du diabète, de l'hypertension, d'une hyperlipidémie, d'une insuffisance cardiaque, de complications diabétiques, du syndrome métabolique, de la sarcopénie, du cancer et analogues, et il présente une activité supérieure. La présente invention concerne un composé représenté par la formule (I): dans laquelle chaque symbole est tel que défini dans le mémoire.
MA35387A 2010-04-27 2011-04-26 Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc. MA34245B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010102718 2010-04-27
PCT/JP2011/060616 WO2011136385A1 (fr) 2010-04-27 2011-04-26 Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.

Publications (1)

Publication Number Publication Date
MA34245B1 true MA34245B1 (fr) 2013-05-02

Family

ID=44120718

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35387A MA34245B1 (fr) 2010-04-27 2011-04-26 Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.

Country Status (24)

Country Link
US (1) US8703758B2 (fr)
EP (1) EP2563765B1 (fr)
JP (1) JP5693611B2 (fr)
KR (1) KR20130094211A (fr)
CN (1) CN103025716B (fr)
AR (1) AR080969A1 (fr)
AU (1) AU2011246004A1 (fr)
BR (1) BR112012027648A2 (fr)
CA (1) CA2797767A1 (fr)
CO (1) CO6640253A2 (fr)
CR (1) CR20120598A (fr)
EA (1) EA021698B1 (fr)
EC (1) ECSP12012311A (fr)
ES (1) ES2546130T3 (fr)
GE (1) GEP20146178B (fr)
MA (1) MA34245B1 (fr)
NZ (1) NZ603777A (fr)
PH (1) PH12012502347A1 (fr)
SG (1) SG185759A1 (fr)
TW (1) TW201206911A (fr)
UA (1) UA108102C2 (fr)
UY (1) UY33354A (fr)
WO (1) WO2011136385A1 (fr)
ZA (1) ZA201208895B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536319T3 (es) 2010-11-30 2015-05-22 Takeda Pharmaceutical Company Limited Compuestos bicíclicos como inhibidores de acetil-CoA carboxilasa (ACC)
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
US8530460B2 (en) * 2011-12-19 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8623860B2 (en) * 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
US20160220557A1 (en) 2013-09-12 2016-08-04 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
JP6050291B2 (ja) * 2014-08-07 2016-12-21 長谷川香料株式会社 ソラノンの製造方法およびその合成中間体
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
CN106636402B (zh) * 2016-12-22 2020-09-15 中南大学湘雅医院 一种判断鼻咽癌放疗敏感性的分子标志物及应用
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
JPWO2023090411A1 (fr) * 2021-11-19 2023-05-25

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
ES2321055T3 (es) 1999-05-05 2009-06-02 Aventis Pharma Limited Compuestos biblicos sustituidos.
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1285651B1 (fr) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Antagonistes de l'hormone concentrant la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
CA2416384A1 (fr) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Derives de sulfonate, leur production et utilisation
CN1642599A (zh) * 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
JPWO2003104230A1 (ja) 2002-06-07 2005-10-06 協和醗酵工業株式会社 二環性ピリミジン誘導体
AU2003278600A1 (en) 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
CA2505322A1 (fr) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Agent de controle de la fonction recepteur
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
EP1630152A4 (fr) 2003-05-30 2009-09-23 Takeda Pharmaceutical Compose cyclique condense
EP1669352A4 (fr) 2003-09-30 2008-12-17 Takeda Pharmaceutical Derive thiazoline et utilisation
EP1695961A4 (fr) 2003-12-17 2007-10-24 Takeda Pharmaceutical Derives d'uree, processus de production correspondant et utilisation
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (fr) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited Derives d'acide phenylpropanoique
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
JPWO2005108370A1 (ja) * 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
GB0511851D0 (en) * 2005-06-11 2005-07-20 Astrazeneca Ab Chemical compounds
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
EP1916234B1 (fr) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Composé d'acide cyclopropanecarboxylique
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007071966A1 (fr) * 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido-[4,5-b]-oxazines pour utilisation en tant qu'inhibiteurs de dgat
EP1996567B1 (fr) * 2006-02-15 2013-09-18 AbbVie Inc. Nouveaux inhibiteurs de l'acetyl-coa carboxylase (acc) et leur utilisation dans les traitements du diabete, de l'obesite et d'un syndrome metabolique
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
RU2454415C9 (ru) 2006-10-19 2013-02-27 Такеда Фармасьютикал Компани Лимитед Производное индола
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
US20100093777A1 (en) 2007-01-25 2010-04-15 Takeda Pharmaceutical Company Limited Spiro-ring compound
EP2128138A1 (fr) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Composé de pyrazole
JP2010517935A (ja) 2007-02-09 2010-05-27 武田薬品工業株式会社 Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (fr) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Composés d'indazole permettant d'activer la glucokinase
JP5613656B2 (ja) 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
CA2730606A1 (fr) 2008-07-16 2010-01-21 Schering Corporation Derives d'heterocycles bicycliques et procedes d'utilisation correspondants
WO2010050445A1 (fr) 2008-10-27 2010-05-06 武田薬品工業株式会社 Composé bicyclique
JP2010102718A (ja) 2009-11-27 2010-05-06 Toshiba Corp 情報処理装置
ES2536319T3 (es) 2010-11-30 2015-05-22 Takeda Pharmaceutical Company Limited Compuestos bicíclicos como inhibidores de acetil-CoA carboxilasa (ACC)
WO2012108478A1 (fr) 2011-02-09 2012-08-16 武田薬品工業株式会社 Composé monocyclique

Also Published As

Publication number Publication date
WO2011136385A1 (fr) 2011-11-03
ECSP12012311A (es) 2013-05-31
EA201291115A1 (ru) 2013-04-30
UY33354A (es) 2011-12-01
CA2797767A1 (fr) 2011-11-03
JP2013525262A (ja) 2013-06-20
PH12012502347A1 (en) 2014-10-14
EA021698B1 (ru) 2015-08-31
ZA201208895B (en) 2014-01-29
CN103025716B (zh) 2014-12-24
SG185759A1 (en) 2012-12-28
CO6640253A2 (es) 2013-03-22
UA108102C2 (uk) 2015-03-25
JP5693611B2 (ja) 2015-04-01
CR20120598A (es) 2013-02-19
BR112012027648A2 (pt) 2019-09-24
US8703758B2 (en) 2014-04-22
EP2563765B1 (fr) 2015-05-27
US20110263562A1 (en) 2011-10-27
TW201206911A (en) 2012-02-16
AR080969A1 (es) 2012-05-23
ES2546130T3 (es) 2015-09-18
AU2011246004A1 (en) 2012-11-29
KR20130094211A (ko) 2013-08-23
EP2563765A1 (fr) 2013-03-06
CN103025716A (zh) 2013-04-03
NZ603777A (en) 2013-08-30
GEP20146178B (en) 2014-10-10

Similar Documents

Publication Publication Date Title
MA34245B1 (fr) Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.
MA34713B1 (fr) Compose bicyclique
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA30890B1 (fr) Compose indole
MA32283B1 (fr) Composes cycliques condenses et utilisation de ceux-ci
MA44021B1 (fr) Composés antitumoraux
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
MA35861B1 (fr) Inhibiteur de la kinase régulant les signaux de l'apoptose
UA94455C2 (en) Oxadiazolidinedione compound
EA200500322A1 (ru) Соединения дигидропиразолопиридина
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA30421B1 (fr) Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1
EA201000751A1 (ru) Производные 7-азаиндола в качестве селективных ингибиторов 11-бэта-гидроксистероида дегидрогеназа 1 типа
WO2009121939A3 (fr) Composés c-aryl glycosides pour le traitement du diabète et de l'obésité
MA33904B1 (fr) Utilisation d'un agent de modification d'hormones surrénaliennes
JOP20210329A1 (ar) مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز
MY181731A (en) Azole benzene derivative
MA33280B1 (fr) Preparation solide
MA39688A (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
MX2015000903A (es) Derivados de carbamato/urea.
NO20070789L (no) Nikotinreseptoragonister for behandling av betennelsessykdommer
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA34556B1 (fr) Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine